Loading company…
Sidera develops therapies for cardiometabolic disorders using insights from human genetics.
Sidera develops medicines for cardiometabolic conditions including diabetes, obesity and cardiovascular disease. The company works with healthcare providers, research institutions and pharmaceutical companies, targeting North America and Europe. Based in Copenhagen, Denmark, it raised USD 109.00 mn in Series A funding on December 8, 2025, with Forbion, Gilde Healthcare, Novo Holdings and RA Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in